Systematic review with meta‐analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis

Costello, Samuel P; Soo, Wei Ting; Bryant, Robert V.; Jairath, Vipul; Hart, Ailsa; Andrews, Jane M.

doi:10.1111/apt.14173

Cited by 229 publications

(180 citation statements)

References 56 publications

Supporting

Mentioning

170

Contrasting

Unclassified

Order By: Relevance

“…A recent Australian randomised controlled trial and a meta‐analysis have supported the use of FMT for induction of remission in patients with ulcerative colitis, 45 , 46 but there are no data to support the use of FMT for remission maintenance. Both studies were small, with less than 100 patients in each.…”

Section: Treatmentmentioning

confidence: 99%

Management of inflammatory bowel disease

Wright

Ding

Niewiadomski

2018

Medical Journal of Australia

View full text Add to dashboard Cite

Summary Australia has one of the highest incidence rates of inflammatory bowel disease (IBD) in the world. Early diagnosis and treatment for IBD is critical. For Crohn disease, in particular, this may change the natural history of disease and reduce disability. Faecal calprotectin is a sensitive test that can be used by primary care physicians to assist in determining which patients with gastrointestinal symptoms may have IBD. This allows for prompt identification of patients who may benefit from endoscopy. Regular re‐evaluation of disease status with strategies that can safely, readily and reliably detect the presence of inflammation with faecal biomarkers and imaging is important. To avoid the risks of cumulative radiation exposure, magnetic resonance imaging and/or intestinal ultrasound, rather than computed tomography scanning, should be performed when possible. Drug treatments for IBD now include five biological drugs listed by the Pharmaceutical Benefits Scheme: adalimumab, infliximab, golimumab, vedolizumab and ustekinumab. Such developments offer the possibility for improved disease control in selected patients.

show abstract

Section: Treatmentmentioning

confidence: 99%

Management of inflammatory bowel disease

Wright

Ding

Niewiadomski

2018

Medical Journal of Australia

View full text Add to dashboard Cite

show abstract

“…Currently, FMT has been approved as a clinical method for treating recurrent CDI by 2013 guidelines and its clinical effectiveness has reached approximately 90% . Moreover, accumulating data indicate that FMT proves beneficial for the treatment of inflammatory bowel diseases and intractable functional constipation, etc . In addition, the observed intestinal dysbiosis in cancer leads to increasing interests in the potential of FMT for the management of cancer.…”

Section: Introductionmentioning

confidence: 99%

Fecal microbiota transplantation in cancer management: Current status and perspectives

Chen

Jin

et al. 2018

Intl Journal of Cancer

237

161

View full text Add to dashboard Cite

The human gut is home to a large and diverse microbial community, comprising about 1,000 bacterial species. The gut microbiota exists in a symbiotic relationship with its host, playing a decisive role in the host's nutrition, immunity and metabolism. Accumulating studies have revealed the associations between gut dysbiosis or some special bacteria and various cancers. Emerging data suggest that gut microbiota can modulate the effectiveness of cancer therapies, especially immunotherapy. Manipulating the microbial populations with therapeutic intent has become a hot topic of cancer research, and the most dramatic manipulation of gut microbiota refers to fecal microbiota transplantation (FMT) from healthy individuals to patients. FMT has demonstrated remarkable clinical efficacy against Clostridium difficile infection (CDI) and it is highly recommended for the treatment of recurrent or refractory CDI. Lately, interest is growing in the therapeutic potential of FMT for other diseases, including cancers. We briefly reviewed the current researches about gut microbiota and its link to cancer, and then summarized the recent preclinical and clinical evidence to indicate the potential of FMT in cancer management as well as cancer‐treatment associated complications. We also presented the rationale of FMT for cancer management such as reconstruction of intestinal microbiota, amelioration of bile acid metabolism, and modulation of immunotherapy efficacy. This article would help to better understand this new therapeutic approach for cancer patients by targeting gut microbiota.

show abstract

“…To date, there have been four RCTs published on FMT in ulcerative colitis (UC), three of which have been published in full6–8 and one of which has only been published in abstract 9. In these four early RCTs, FMT induced clinical remission in 28% of patients compared with 9% of patients in the placebo groups 10. There have been no RCTs published to date in Crohn’s disease (CD); however, scattered case reports and cohort studies show promise 11…”

Section: Introductionmentioning

confidence: 99%

Faecal microbiota transplantation as a treatment for inflammatory bowel disease: a national survey of adult and paediatric gastroenterologists in the UK

Mcilroy

Nalagatla

Hansen

et al. 2018

Frontline Gastroenterol

View full text Add to dashboard Cite

show abstract

Systematic review with meta‐analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis

Abstract: SummaryBackground: Faecal microbiota transplantation (FMT) is emerging as a novel therapy

Cited by 229 publications

References 56 publications

Management of inflammatory bowel disease

Management of inflammatory bowel disease

Fecal microbiota transplantation in cancer management: Current status and perspectives

Faecal microbiota transplantation as a treatment for inflammatory bowel disease: a national survey of adult and paediatric gastroenterologists in the UK

Contact Info

Product

Resources

About